Advances in Heart Failure: A Year of Discovery – SGLT2 Inhibitor Trials and Implications for Practice
Published: 20 August 2020
-
Views:
57
-
Likes:
7
-
Views:
57
-
Likes:
7
-
20m 30sPart 1 SGLT2 Inhibition in Changing the HF Paradigm Andrew JS Coats, Piotr Ponikowski, Stefan Anker
-
19m 8sPart 2 Latest Evidence for SGLT2 in HF – 2020 So Far Andrew JS Coats, Piotr Ponikowski, Stefan Anker
-
15m 58sPart 3 Latest Evidence and Key Upcoming HFrEF Data 2020 Andrew JS Coats, Piotr Ponikowski, Stefan Anker
Overview
This programme focuses on assessing recent data on SGLT2 inhibitors that show they reduce CV outcomes, HF hospitalisations and mortality in HFrEF patients irrespective of T2DM .
The expert panel also discuss how these agents should be utilised in clinical practice within GDMT, as well as considering potential application of the agents in HFpEF
Learning Objectives
- Evaluate Emerging Data on the Treatment of Heart Failure With SGLT2 Inhibitors in Patients With or Without T2DM
- Interpret the New Data on the Treatment of Heart Failure With SGLT2 Inhibitors in Patients With or Without T2DM in Relationship to the Existing Data
- Understand the Implementation of the Emerging Data on the Treatment of Heart Failure With SGLT2 Inhibitors in Patients With or Without T2DM for Clinical Practice
More from this programme
Part 1
SGLT2 Inhibition in Changing the HF Paradigm
Part 2
Latest Evidence for SGLT2 in HF – 2020 So Far
Part 3
Latest Evidence and Key Upcoming HFrEF Data 2020
Part 4
The Future is Near – Unmet Needs in HFpEF
Faculty Biographies
Carolyn Lam
Professor and Senior Consultant
Dr Carolyn Lam is a Senior Consultant of the National Heart Centre, Singapore and Professor of Duke-NUS Cardiovascular Academic Clinical Program. Dr Lam’s clinical sub-specialty is heart failure, and she is recognized globally for her expertise in heart failure with preserved ejection fraction. She also has expertise in women’s cardiovascular disease, hemodynamics, echocardiography, biomarkers and clinical trials.